Question-and-Answer Session
Operator
(Operator Instructions) Your first question will come from the line of Michael Aberman with Credit Suisse.
Michael Aberman - Credit Suisse
Thank you for taking the question. Can you give us a little better color what we should be looking at in terms of PK in the multi-dose study for the L-Dopa product?
Ron Barrett
Yes, this study will be a crossover study in healthy subjects, in which Sinemet will be dosed multiple times a day and 279 will be dosed multiple times a day and what we’re looking for is a reduction in the peak trough ratio throughout the full day. We’re collecting PK for 24 hours.
Michael Aberman - Credit Suisse
Is there any reduction in the number of pills per day for your product or when you say multiple times enable, what’s the anticipation do you think, based on the single dose that you could have fewer pills per day?
Ron Barrett
Well, discussions we’ve had with experts, they’re more concerned about the flatness of the PK profile than necessarily the number of doses per day and so this study will examine three times a day Sinemet versus three times a day 279. With the single dose data that we have, we would predict a very flat profile for 279 and one which achieves what we believe to be therapeutic concentrations rapidly on the first dose of the day and extends those levels throughout the day in a flat manner.
One other thing that we’ve been discussing with experts is at the end of the day, how long you want to peak the L-Dopa exposure to be maintained and so this formulation would allow some flexibility there depending on how many times a day you dosed it. This particular experiment is going to be three times a day. Whether we end up with that eventually, I think it depends in late stage patients where you really want to have this flat profile I earlier patients twice a day with this product. With the profile that we have, probably it’s going to be acceptable also.
Michael Aberman - Credit Suisse
Thanks.
Ron Barrett
You’re welcome.
Operator
And your next question will come from the line of David Amsellem with Piper Jaffray.
David Amsellem - Piper Jaffray
(Inaudible) David Amsellem and Johnson. Thanks for taking my question. My first is a follow-up asked from the first question. Can you talk about you how you believe the tolerability of 279 differs from conventionally levodopa or carbidopa treatment?
- To read the full transcript on Seeking Alpha, click here »
